Magazines and books

Publications and Presentations

Published data and presentations from medical conferences for Karyopharm’s investigational drug candidates

This page is intended to provide scientific information to scientific research professionals. XPOVIO (selinexor) has only been approved by the United States Food and Drug Administration (FDA) for the following indications:

• In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

• For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Conditional Marketing Authorization from the European Commission granted on March 29, 2021: NEXPOVIO is indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

On May 26, 2021 the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for NEXPOVIO® (selinexor), in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Karyopharm’s other drug candidates, including selinexor in additional indications, are investigational medicines and have not been approved by FDA, Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.  

Featured Research

Multiple Myeloma

Published Research

  1. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, Phase 3 trial
  2. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
  3. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
  4. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
  5. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
  6. Consensus Recommendations for the Clinical Management of Patients with Multiple Myeloma Treated With Selinexor
  7. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy
  8. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH
  9. Overall survival with oral selinexor plus low dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma

Posters and Presentations

  1. Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Patients with Multiple Myeloma (MM) After 1-3 Prior Therapies: Initial Results of the Phase 3 BOSTON Study
  2. Selinexor, Daratumumab, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM)
  3. Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Heavily Pretreated Multiple Myeloma
  4. Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma
  5. Selinexor, Lenalidomide, and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
  6. Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
  7. Results of the Pivotal STORM Study (Part 2): Deep and Durable Responses with Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Exposed and Triple Class Refractory MM
  8. Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated With Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
  9. Selinexor Combined with Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate in Patients with Relapsed or Refractory Multiple Myeloma (MM)
  10. Improved Overall Survival (OS) with Oral Selinexor Plus Low Dose Dexamethasone (Sd) in Patients with Triple Class Refractory Multiple Myeloma (TCR-MM) Compared to FLATIRON – Real World Evidence
  11. Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selienxor, Bortezomib, and Dexamethasone in Comparison with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis From the BOSTON Study
  12. Once Weekly Selinexor, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses From the Phase 3 BOSTON Study
  13. Impact of Prior Therapies on the Safety and Efficacy of Once-Weekly Selinexor, Bortezomib, and Dexamethasone Compared With Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the BOSTON Study
  14. Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 BOSTON Study

Diffuse Large B-cell Lymphoma (DLBCL)

Published Research

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
  2. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
  3. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement

Posters and Presentations

  1. A Phase 2b Study of Selinexor in Patients with Relapsed / Refractory Diffuse Large B-Cell Lymphoma: SADAL Trial
  2. Survival Among Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Single Agent Selinexor in the SADAL Study
  3. Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients With Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
  4. Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Subset Analysis from the SADAL Pivotal Phase 2b Study
  5. Selinexor Efficacy and Safety are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis From the Pivotal Phase 2b SADAL Study

Other Hematologic Malignancies

Published Research

  1. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
  2. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
  3. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Posters and Presentations

  1. A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL study)
  2. Frontline Selinexor and Chemotherapy is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)
  3. Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents
  4. Phase I Trial of the Selective Inhibitor of Nuclear Export, SELINEXOR, in Relapsed Childhood Leukemia
  5. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML
  6. A Phase I/II study of Selinexor (SEL) with Sorafenib in Patients with Relapsed and/or Refractory FLT3- mutated Acute Myeloid Leukemia (AML)
  7. A Randomized, Open-Label, Phase 2 Study of Selinexor Versus Physician’s Choice (PC) in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Solid Tumors

Published Research

  1. Phase 2 Study of the Exportin 1 Inhibitor Selinexor in Patients with Recurrent Gynecological Malignancies
  2. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
  3. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Posters and Presentations

  1. SEAL: Phase 3, Randomized, Double Blind, Cross-Over, Study of Selinexor versus Placebo in Advanced Unresectable DeDifferentiated Liposarcoma (DDLS)
  2. SIENDO/ENGOT-EN5: A randomized phase 3 trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer
  3. Final Results of the KING trial: Phase 2 Study of Efficacy, Safety, and Intratumoral Pharmacokinetics of Selinexor (KPT-330) Monotherapy in Recurrent Glioblastoma
  4. Phase 2 Results of Selinexor in Advanced DeDifferentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Cross-Over Study
  5. Results of a Phase II Trial of Selinexor, in Patients with Gynaecological Cancers
  6. Phase 1b study to evaluate the safety of selinexor in combination with pembrolizumab in patients with advanced malignancies – The melanoma experience
  7. Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study

Mechanism of Action

  1. The Past, Present, and Future of CRM1/XPO1 inhibitors
  2. Inhibiting cancer cell hallmark features through nuclear export inhibition
  3. The nuclear export protein XPO1-from biology to targeted therapy
  4. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives
  5. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

Eltanexor and KPT-9274

  1. Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents
  2. Eltanexor (KPT-8602), a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
  3. Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma
  4. A First in Human Phase 1 Study of KPT-9274, a First in Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or NHL
  5. PAK4 Inhibition Improves PD-1 Blockade Immunotherapy

COVID-19

  1. Treatment of Severe COVID-19 with Low-Dose Selinexor: Demonstration of Anti-Viral and Anti-Inflammatory Activities in a Randomized, International, Multicenter, Placebo-Controlled Phase 2 Clinical Trial

Archived Posters & Publications